Glenmark Pharmaceuticals, USA (Glenmark), has recently announced the launch of Axitinib Tablets, 1 mg and 5 mg. This product is an Authorized Generic version of INLYTA (axitinib) tablets.
According to IQVIA sales data for the 12-month period ending September 2026, U.S. annual sales of INLYTA Tablets were approximately USD 538.4 million.
Marc Kikuchi, President & Business Head, North America, also commented on this launch.
He added, “The launch of Axitinib Tablets reinforces Glenmark’s commitment to expanding access to quality, affordable medicines for patients in the United States. By adding this important product to our portfolio, we continue to strengthen our focus on addressing the evolving needs of patients and healthcare providers.”
Last news about this category
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy